Accordingly, MR antagonists, such as eplerenone and spironolactone, have been shown to reverse hypertension- and diabetes-associated vascular dysfunction (Swaminathan et al., 2008; Schafer et al., 2010; Briones et al., 2012). This evidence concerns the gene NR3C2 and diabetes mellitus.